FEP方案治疗晚期和转移性胃癌的临床研究

Efficacy of FEP (5-fluorouracil,epirubicin,cisplatin) combination regimen in the treatment of patients with advanced or metastatic gastric cancer.

目的研究FEP方案治疗晚期和转移性胃癌的疗效和毒副反应。方法5-Fu 500mg／m^2，静滴6小时以上，第1～5天；EPI60rag／It／，第1；DDP25～30me／m^2，第1～3天，21天为一周期，完成两周期及以上者作疗效评定。结果34例患者其中CR2例（5．9％），PRl2例（35．3％），SD13例（38．2％），PD7例（20.6％），总有效率41．2％，中位缓解期7．9个月，中位生存期10．8个月，1年生存率40．3％。毒副反应以骨髓抑制、胃肠道反应及脱发为主。结论FEP方案治疗晚期和转移性胃癌有效，毒副反应可耐受。

Objective To evaluate the efficacy and safety of FEP （5 - fluorouracil,epirubicin,cisplatin） combination regimen in treatment of patients with metastatic or advanced gastric cancer （ M/AC.C ）. Methods Of the 34 eligible patients with measurable M/AC.C, all received 5-fluorouracil 500mg/m^2, protracted venous infusion over six hours on day1 - 5 ,epirubicin 60mg/nf on day 1, cisplatin25 - 30mg/m^2 on day 1 - 3, repeated every 21days for at least two courses. Results All 34 patients assessable for response and toxicity, there were 2 complete responses, 12 partial responses, 13 stable diseases and 7 progressed diseases, overall response rate was 41.2% ,and the median duration of response was 7.9 months, median survival was 10.8 months, and 1 year survival rate 40.3%. Toxicity from treatment mainly included myelosuppression, emesis, mucositis and alopecia. Conclusion FEP regimen is effective and with tolerable toxicity in M/AC.C treatment.